Biotheus Inc.

We are thrilled to celebrate the grand opening of our biologics (DS/DP) manufacturing facility in Nantong 🎉. At this state-of-the-art facility, we have 3 x 2000L lines dedicated to supporting the global development of our pipeline. #Biologics #Manufacturing

Bispecific antibodies, a novel class of immunotherapies, are showing significant promise in oncology. These engineered antibodies can simultaneously bind to two different antigens, providing unique mechanisms of action. Hematological malignancies are the primary focus of bispecific antibody development. Fast forward to 2022–2023, and we witnessed a dynamic shift, with eight new bispecific approvals, primarily revolutionizing hematological cancer treatments. Nevertheless, numerous bispecific antibodies are under investigation for various solid tumors, including gastric, colorectal, ovarian, prostate, and Lung cancer. Immunocore, Innovent Biologics, Johnson & Johnson Innovative Medicine, Roche, Curonix, Genmab, AbbVie, Merus N.V., Summit Therapeutics, Inc., BioNTech SE, Affimed, Biotheus Inc., Amgen, Regeneron, Qilu Pharmaceuticals, and others showcased their latest research and advancements in bispecific treatments at the American Society of Clinical Oncology (ASCO) 2024. Get an in-depth analysis of bispecific antibodies coverage from the ASCO 2024 conference at https://lnkd.in/gwDBMuqP

We have strengthened our partnership with Hansoh Pharmaceuticals on PM1080/HS-20117, a EGFR x cMET bispecific, for development of an ADC product. I would like to thank the team at Hansoh for believing in the potential of PM1080 and excited by their vision in the ADC space. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Biotheus Inc.

Exciting news!

Meet our senior team in San Francisco for JPM2024!

We are delighted to announce that our collaboration with BioNTech SE has been bolstered by the inclusion of the promising IO bispecific agent PM8002 (PD-L1 x VEGF). We are excited about the global development of PM8002 for future innovate combination therapies.

Western companies struck seven times more deals to access Chinese innovation last year than in 2013, and 2023 is on track to show another increase. Meanwhile, Western biotechs continue to monetize pipelines by out-licensing to China and Asia. What are MNCs and Westerns looking for as they pursue partners and assets in Asia and how can Asian #biotechs position themselves to find the best deal to maximize their growth? A panel of experienced #dealmakers from MNCs and China and Western biotechs will discuss the latest trends, what they are looking for, and share best practice and lessons learned in recent deals. Join us next week in Shanghai at the #BioCenturyChinaSummit: https://ow.ly/spRc50Q0OMr View the agenda, who you will meet, and more: https://ow.ly/gJ3p50Q0OMs Session Chair: Jeff Cranmer, Executive Director, Business Development & Host, "BioCentury This Week" Podcast, BioCentury Inc. Panelists: Philippe Alen, Head of Business Development, Galapagos Jun Bao, Ph.D., Chief Business Officer, Biotheus Inc. Harm-Jan Borgeld, Ph.D., Global Head, Asia, Partnering, Roche Wenseng "Wendy" Pan, Ph.D., Partner, Goodwin Dan Wang, M.D., Head of APAC, The Janssen Pharmaceutical Companies of Johnson & Johnson

Check out our latest results for PM8002 (anti-PD-L1 x VEGF-A) and PM1003 (PD-L1 x 4-1BB) at ESMO Congress 2023 in Madrid! Meet with our clinical team and collaborating physicians to learn more. Saturday, 21 October: 1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC) Monday, 23 October: 1036P - A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors https://lnkd.in/dVD7C2im